ArticleClinical diabetes : a publication of the American Diabetes Association2023
Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study.
Article in Clinical diabetes : a publication of the American Diabetes Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.JAMA network open · 2026Pooled it
- Causes and consequences of discontinuation of GLP1RAs or tirzepatide.Nature reviews. Endocrinology · 2026Review
- Prescription patterns of SGLT2 inhibitors in patients admitted to a tertiary health service with heart failure with reduced ejection fraction: an opportunity to improve.Internal medicine journal · 2026Article
- Nonmedical Factors That Influence Diabetes Complications and Multilevel Strategies to Reduce Disparities and Improve Outcomes in the U.S.Diabetes care · 2026Article
- Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers.Healthcare (Basel, Switzerland) · 2026Article
- Polish healthcare professionals' perceptions of GLP-1 receptor agonists in cardiometabolic risk reduction: a cross-sectional online survey in Poland.Frontiers in endocrinology · 2026Article
- Global Pain Management Trends and Barriers to Care in Hidradenitis Suppurativa.Dermatology (Basel, Switzerland) · 2026Article
- Knowledge, attitudes, and practices of Saudi physicians toward the use of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus: a nationwide cross-sectional study.Frontiers in endocrinology · 2026Article
- Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report.Cureus · 2026Article
- Comparative Weight Change With Initiation and Adherence to Common Medications for Type 2 Diabetes.Obesity (Silver Spring, Md.) · 2025Article
- Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART.CJC open · 2025Article
- Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial.American heart journal · 2025Article
- Primary Care Physicians' Perspective on SGLT2 Inhibitors for Chronic Kidney Disease.Kidney medicine · 2025Article
- Pancreatitis, Type 2 Diabetes Mellitus, and Pancreatic Cancer (Diabetes Metab J 2025;49:252-63).Diabetes & metabolism journal · 2025Article
- Article
- A National Physician Survey Examining Switching From Sulfonylureas or Insulin to Newer Diabetes Medications.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Physician self-reported factors driving clinical decision-making in management of patients with T2D and ASCVD/high risk of ASCVD across the middle East and Africa: a cross-sectional study.Frontiers in pharmacology · 2025Article
- Knowledge, Counseling Practice, Perceived Barriers, and Clinical Decision-Making of Community Pharmacists in Saudi Arabia Regarding Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This survey study evaluated type 2 diabetes medication prescribing patterns of health care providers in different specialties and of different professional designations or levels of training at an academic health care system and sought to identify factors influencing medication choices and uncover barriers to prescribing glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. High cost and the need for prior authorizations were reported as the main barriers to prescribing drugs in these two classes, along with a lack of experience among some specialists. Greater system support to decrease the administrative burden of prescribing newer medications and greater dialogue among the specialties caring for patients with cardiorenal comorbidities can improve prescribing of these drugs in accordance with clinical practice recommendations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.